Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
NCT05776524
Recruiting
The objective of this research is to find out what effects (good and bad), the combination of gemcitabine and nab-paclitaxel therapy (GEM-ABR for the rest of the document), standard chemotherapy for pancreatic cancer, and the TheraBionic device has on participants' condition.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Pancreatic Cancer, Metastatic Adenocarcinoma
Register for Updates
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
NCT05947071
Recruiting
Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV). Recent studies have investigated two strategies to overcome poor immune responses in SOT recipients: (1) administration of high-dose (HD)-IIV compared to SD-IIV and (2) two doses of SD-IIV compared to one dose of SD-IIV in the same influenza season. One study compared HD-IIV vs. SD-IIV in adult SOT rec... Read More
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
03/20/2025
Locations: Stanford University, Stanford, California +7 locations
Conditions: Immunization; Infection, Transplantation Infection, Influenza
Register for Updates
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
NCT06280391
Recruiting
ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive). Study details include: * The study duration (screening, 24-52-week treatment, 20-week safety follow-up) will be up to 47-77 weeks. *... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/20/2025
Locations: University of Alabama at Birmingham- Site Number : 8400040, Birmingham, Alabama +139 locations
Conditions: Bronchiectasis
Register for Updates
Blood Flow Restriction Training for People With Disabilities
NCT06441422
Recruiting
A large portion of the American population live with disabilities. People with disabilities can find it difficult to perform standard exercise routines. Regular exercise is necessary to be healthy, especially as people age. Lack of exercise can lead to secondary health concerns, like loss of muscle mass, diabetes, heart attack or stroke, to name a few. For exercise to be most beneficial, a certain degree of intensity must be achieved. Low load blood flow restriction training may be able to mimic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Weakness, Muscle
Register for Updates
Benefits of Choir for Older Adults with Unaddressed Hearing Loss (WP2)
NCT06580847
Recruiting
Unaddressed age-related hearing loss is highly prevalent among older adults, typified by negative consequences for speech-in-noise perception and psychosocial wellbeing. There is promising evidence that group singing may enhance speech-in-noise perception and psychosocial wellbeing. However, there is a lack of robust evidence, primarily due to the literature being based on small sample sizes, single site studies, and a lack of randomized controlled trials. Hence, to address these concerns, this... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/20/2025
Locations: Brain and Creativity Institute, University of Southern California, Los Angeles, California +6 locations
Conditions: Hearing Loss, Age-Related, Speech Intelligibility, Psychosocial Functioning
Register for Updates
Efficacy and Safety of VDPHL01 in Males with AGA
NCT06724614
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
03/20/2025
Locations: Site 36, Birmingham, Alabama +43 locations
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Register for Updates
Effects of Photobiomodulation (PBM) on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients
NCT06819033
Recruiting
The purpose of this study is to compare the efficacy of laser photobiomodulation and "Magic Mouthwash" for treatment of pain in pediatric patients with aphthous ulcers , to assess how photobiomodulation influences the rate of healing of aphthous ulcers in pediatric patients and to measure changes in pain levels reported by pediatric patients undergoing photobiomodulation treatment for aphthous ulcers.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
03/20/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Aphthous Ulcer
Register for Updates
Effect of Daily Mixed Spice Consumption on Memory Function
NCT06889961
Recruiting
The aging process entails a multitude of structural and functional alterations within the brain, culminating in a gradual and progressive decline in cognitive function. Recent research has indicated that various spices may hold the key to enhancing brain health and combating the effects of aging on cognitive abilities. The hypothesis is that a mixture of spices, acknowledged for their reported memory protection potential, may yield a more potent beneficial effect on memory function than a single... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
03/20/2025
Locations: UCLA Center for Human Nutrition, Los Angeles, California
Conditions: Memory, Cognitive Function
Register for Updates
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
NCT00588185
Recruiting
This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread.
Gender:
MALE
Ages:
All
Trial Updated:
03/20/2025
Locations: Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey +6 locations
Conditions: Prostate Cancer
Register for Updates
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
NCT03617237
Recruiting
Registry database repository for determining clinical outcomes primarily of patients who have received or have been evaluated for radiation treatment in either the definitive or palliative setting for both malignant and benign etiologies. To compare the outcomes with National Cancer Data Base (NCDB) of the American College of Surgeon(ACS).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/20/2025
Locations: UT Southwestern Medical Centre, Dallas, Texas
Conditions: Cancer
Register for Updates
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
NCT04499053
Recruiting
This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection will be eligible. Patients will receive standard platinum-based chemotherapy plus durvalumab for 4 cycles (every 3 weeks), followed by durvalumab (with or without pemetrexed for non-squamous NSCLC) maintenance therapy. It is hypothesized that Durvalumab and tremelimumab in combination wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia +3 locations
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
NCT04958811
Recruiting
To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia +1 locations
Conditions: Non-squamous Non-small-cell Lung Cancer
Register for Updates